Latest filing published 14 May 2025 for BridgeBio Pharma, Inc., €184.9M.
Filing timeline
BuySaleInsider track record
Closed purchases
Not enough history yet: 1 closed purchase, at least 2 are needed.
Purchases by company
Since each purchase
- +2.3%Entry US$28.99 · Close at T+365 US$29.67
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
KKR Genetic Disorder L.P.: trading record in brief
KKR Genetic Disorder L.P. is a declared insider of BridgeBio Pharma, Inc., with filings sourced from SEC (Form 4). We count 7 filings; the first trade dates from 1 July 2019 and the latest from 12 May 2025.
Both buying and selling appear: 1 purchase worth €39.9M, against 5 sales worth €750.4M. Taken together, the sales exceed the purchases by €710.5M. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. So far in 2025, the count stands at no purchases and 2 sales.
The latest filing, published on 14 May 2025, reports an open-market sale of €184.9M in BridgeBio Pharma, Inc. The clock since the last published purchase (3 July 2019) now reads 2,686 days. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. For comparison, the SEC allows two business days to file a Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Companies and markets linked to KKR Genetic Disorder L.P.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 6,000,000 shares@ US$34.2036.6% of flowCommon StockSEC:0001140361-25-019003:0
- 6,000,000 shares@ US$32.9636.8% of flowCommon StockSEC:0001140361-25-007699:0
- 5,800,000 shares@ US$25.7526.7% of flowCommon StockSEC:0001140361-24-041329:0
- 3,450,000 shares@ US$60.468821.8% of flowCommon StockSEC:0001140361-21-005267:0
- 2,389,690 shares@ US$33.3912.5% of flowCommon StockSEC:0001140361-20-012852:0
- 34,253,561 sharesCommon StockSEC:0000899243-19-019173:0
- 2,647,100 shares@ US$17.006.5% of flowCommon StockSEC:0000899243-19-019173:1Canonical exit: 29 Sept 2019 (T+90)
7 of 7 declarations
